Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (20143)	3/26/1999 4:10:00 PM
From: Joe Fang	Respond to of 23519

OT to VLAD... I think you have me on your shareholder list. The number of shares to date is 26,950 shares (in cash account of course) TIA JF

To: VLAD who wrote (20143)	3/26/1999 10:07:00 PM
From: Cacaito	Read Replies (2) \| Respond to of 23519

There are two suppliers of PGE1 to the world market (if I remember well) they are in Eastern Europe (Czech, Hungary?) and Vivus get their product there. Does P&U get their PGE1 there? does Schwarz Pharma? Could Vivus buy out those suppliers or one of them? or merge? antitrust issues? PGE1 is also use in some congenital heart disease in babies (a very small market). There is a prostaglandin (PGE2) use for induction of labor (same PGE producers?). If they get hold to this chemical company they could (probably) bring the costs of Muse and Alibra down a lot. (if that company is small). Probably not, they or P&U would already done it. Just musing around.